← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 11.6% to $12.4M, while Net income increased 23.0% to ($7.0M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $12.4MWatch
- Profitability — Net income ($7.0M)Watch
- Cash generation — Free cash flow ($3.1M)Note
- Accounting — Formula distress score · manipulation and earnings-quality screens not computedWatch
- Insiders — 1 buys; 5 sells in 365 daysOK
- Capital — dividends paid were $388.4KNote
Business
Reliance Global Group, Inc.: Effective January 26, 2026, we changed our ticker symbol on the Nasdaq Capital Market from "RELI" to "EZRA." We operate as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses.
Where the revenue comes from
Fiscal 2025, as Reliance Global Group, Inc. reports it. History and quarterly detail are in the app.
- Medical$9.1M
- Property And Casualty$3.2M
- Life$115K
Leadership changes
From Reliance Global Group, Inc.'s own filings, the day they're filed.
- Judah Korman · Chief Operating Officer · appointmenteff. 2026-06-18
- K. Zack Wilder · Chief Technology Officer · appointment
- Mordy Beyman · President · appointment
Latest filings
- 8-K · Company announcement2026-09-03
- 8-K · Company announcement2026-08-27
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-08-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Reliance Global Group, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.